Pembrolizumab after complete bladder cancer treatment response
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your bladder cancer must be muscle-invasive (about stages cT2 to cT4), with no spread to lymph nodes or distant sites (N0M0)
- You must have had full “trimodality” treatment, including the most complete TURBT surgery possible, and then had a complete response checked 28–90 days after treatment ended
- The cancer should be measurable on scans, and if a spot was in an area that was previously radiated, it must show progression there
- You should be well enough to do daily activities (ECOG 0 to 2) and your organs (blood, liver, kidneys) must meet lab requirements
- You should not have had prior treatment with immune checkpoint drugs like pembrolizumab, nivolumab, or atezolizumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.